Toviaz (fesoterodine)
- Region
- 🇪🇺 EU
- Active substance
- fesoterodine
- Company
- Pfizer Europe MA EEIG
- Status
- Authorised
- Therapeutic area
- Urinary Bladder, Overactive
- EU approval
- Fri 20 Apr 2007
- Application
- EMEA/H/C/000723
- ATC
- G04BD11
- Official record
- www.ema.europa.eu
Indication
Treatment of the symptoms (increased urinary frequency and / or urgency and / or urgency incontinence) that may occur in patients with overactive-bladder syndrome.
Regulatory milestones
No milestones recorded in the last year.
Follow Toviaz
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.